The Chronic Kidney Disease Solution Reviews: Publishes 2026 Consumer Evidence Guide on CKD Testing and Health Program

Updated consumer resource explains eGFR and UACR testing, individualized nutrition, medication oversight and how to distinguish established CKD guidance from unsupported “reversal,” “repair” and “detox” claims

BOISE, Idaho, September 17, 2026 — Blue Heron Health News, publisher of The Chronic Kidney Disease Solution by Shelly Manning, has prepared a 2026 consumer evidence guide focused on helping readers evaluate chronic kidney disease information found online. The guide places laboratory testing, individualized medical care and source verification ahead of claims based solely on symptoms, testimonials, individual foods, supplements or general wellness concepts.

The updated guidance was developed in response to the wide range of kidney-health information available to consumers, including commercial programs and online articles that may use terms such as “reverse,” “restore,” “repair” or “detox” without demonstrating that the complete program itself has been evaluated in controlled clinical research.

The guide does not state that The Chronic Kidney Disease Solution cures, reverses or treats chronic kidney disease. It instead explains how consumers can compare health information with established clinical measures and current guidance from organizations including the Centers for Disease Control and Prevention, National Institute of Diabetes and Digestive and Kidney Diseases and Kidney Disease: Improving Global Outcomes.

“People searching for kidney information can encounter strong promises before they understand what their eGFR or urine albumin results mean,” said Shelly Manning, author of The Chronic Kidney Disease Solution. “The purpose of this guide is to encourage readers to separate educational lifestyle information from medical evidence and to discuss their own laboratory results, medications and nutrition needs with qualified healthcare professionals.”

Why CKD Testing Is Central to the Updated Guide

Chronic kidney disease is common and often not obvious in its earlier stages. According to the Centers for Disease Control and Prevention’s 2026 national estimates, approximately 37 million U.S. adults, or about 14% of the adult population, have CKD. CDC estimates also indicate that approximately 87% of adults aged 20 or older who have CKD are unaware that they have the condition.

That low level of awareness is one reason the new consumer guide emphasizes testing rather than symptom-based self-assessment.

A person can have reduced kidney function or kidney damage without experiencing symptoms that clearly identify CKD. Conversely, general symptoms such as tiredness, changes in appetite or swelling can have many possible causes and cannot establish a CKD diagnosis on their own. The National Institute of Diabetes and Digestive and Kidney Diseases identifies estimated glomerular filtration rate, or eGFR, and urine albumin as two key markers used in evaluating kidney disease.

eGFR estimates how effectively the kidneys are filtering blood. Urine albumin testing, commonly reported as the urine albumin-to-creatinine ratio or UACR, helps identify abnormal leakage of albumin into urine. These measures provide different information and are often interpreted together.

A Single Creatinine Result Does Not Tell the Entire Story

The guide also cautions against drawing broad conclusions from a single creatinine result. Serum creatinine is used in estimating GFR, but creatinine levels can be influenced by factors unrelated to kidney disease, including muscle mass and other individual characteristics.

NIDDK notes that eGFR generally provides more useful information about kidney filtration than serum creatinine considered by itself. UACR provides another dimension by measuring albumin in urine. NIDDK identifies a UACR greater than 30 mg/g as a possible sign of kidney disease, although abnormal results may require repeat testing and clinical interpretation.

Changes over time can also matter. A healthcare professional may consider current eGFR, albuminuria, previous laboratory results, diabetes status, blood pressure, cardiovascular health, age, medications and the suspected cause of kidney disease when determining appropriate care.

The updated guide therefore advises readers not to interpret a temporary change in one laboratory value as proof that damaged kidney tissue has been restored.

CKD Care Is Increasingly Based on Risk, Not a Universal Protocol

The 2024 KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease emphasizes classification, risk assessment and individualized management. Modern CKD care does not depend on one universal diet, supplement or lifestyle protocol for everyone diagnosed with kidney disease.

Treatment decisions can differ substantially between individuals depending on the cause and stage of CKD, albuminuria, rate of progression, cardiovascular risk, diabetes, medications and other health conditions. The Chronic Kidney Disease Solution consumer guide uses this distinction to explain why a recommendation that may be reasonable for one person should not automatically be applied to every person with CKD.

It also cautions readers against stopping or changing prescription medications because of advice contained in an online program, book, video or supplement advertisement. Medication decisions should remain under the supervision of the prescribing healthcare professional.

Established CKD Management Includes Medical Treatment

Lifestyle choices can be important in chronic disease management, but the guide makes clear that they should not be presented as substitutes for established medical care. NIDDK identifies blood-pressure management as an important part of slowing CKD progression. ACE inhibitors and angiotensin receptor blockers, or ARBs, can have kidney-protective roles in appropriately selected patients, particularly in people with albuminuria.

Current KDIGO recommendations also include sodium-glucose cotransporter-2 inhibitors, commonly called SGLT2 inhibitors, for several groups of adults with CKD when specific clinical criteria are met. These medications require individualized clinical decision-making.

The consumer guide therefore does not advise readers to replace an ACE inhibitor, ARB, SGLT2 inhibitor, diabetes medication or other prescribed treatment with a dietary program or natural-health protocol. Instead, it encourages readers to bring questions about lifestyle changes to their physician, nephrologist, pharmacist or other qualified healthcare professional.

Kidney Nutrition Is Individualized

Nutrition is another area where general online advice can become misleading when presented without context. NIDDK states that nutritional needs can change as CKD progresses. Sodium, potassium, phosphorus, protein and fluid intake may need to be adjusted according to kidney function, laboratory measurements, medications and other health conditions.

For example, potassium should not automatically be restricted for everyone with CKD. Some people need to limit potassium because blood concentrations are elevated, while others may not require the same restriction. Protein intake also requires context.

KDIGO’s 2024 guideline suggests maintaining approximately 0.8 grams of protein per kilogram of body weight per day for adults with CKD stages G3 through G5, while cautioning against high protein intake in people at risk of progression. More intensive protein restriction, when appropriate, requires professional supervision and is not suitable for everyone.

KDIGO also recommends tailoring dietary changes involving sodium, phosphorus, potassium and protein to the person’s individual needs, disease severity and other conditions. The guide therefore avoids describing any single “kidney diet” as universally appropriate.

Why “Kidney Detox” Claims Require Additional Scrutiny

The guide devotes a section to detox and kidney-cleansing claims because the kidneys already play a central physiological role in removing waste and maintaining fluid and electrolyte balance. Reduced kidney function can also affect how the body handles medications, minerals and other substances.

This means that adding supplements, herbal preparations or highly restrictive diets without professional oversight may create risks rather than necessarily improving kidney health. Consumers are encouraged to disclose vitamins, minerals, herbal products, nonprescription medicines and supplements to their healthcare providers.

The guide also recommends particular caution when a commercial product or program claims that a supplement can prevent dialysis, regenerate kidney tissue, permanently reverse CKD or replace prescribed treatment without presenting appropriate clinical evidence involving the product itself.

Ingredient Research Is Not Program-Level Evidence

One of the central evidence principles included in the guide is the difference between research on an individual ingredient and research on a finished commercial program.

A study investigating a particular food, fiber, vitamin, probiotic organism or dietary pattern may provide useful scientific information. It does not automatically demonstrate that a commercial program incorporating that concept produces the same outcome.

The Federal Trade Commission’s health-products guidance states that health-related advertising must be truthful, not misleading and appropriately substantiated. FTC guidance further explains that when a finished product contains multiple ingredients, evidence involving one ingredient may not be sufficient to substantiate a claim about the finished product.

For serious disease-related efficacy claims, the evidentiary standard is correspondingly high. The Chronic Kidney Disease Solution guide applies the same principle to its own materials: references to nutrition, blood pressure, gut-health research or other lifestyle topics should not be interpreted as a clinical trial of The Chronic Kidney Disease Solution itself.

No program-level randomized controlled trial establishing that the complete commercial program reverses CKD is presented in the materials reviewed for this release.

FDA Rules Also Matter When Consumers Evaluate Health Claims

U.S. Food and Drug Administration guidance provides another useful distinction. FDA states that a product marketed as a dietary supplement cannot lawfully be represented as diagnosing, treating, curing or preventing a disease unless it meets the regulatory requirements applicable to drugs.

Although The Chronic Kidney Disease Solution is a digital educational program rather than a dietary supplement, the broader distinction remains useful for consumers evaluating accompanying supplement recommendations or product advertisements. A disclaimer alone does not transform an unsupported disease-treatment claim into established medical evidence.

The guide therefore encourages consumers to examine the complete message being communicated rather than relying solely on words such as “natural,” “research-based” or “clinically inspired.”

Four Questions Consumers Can Ask When Evaluating a Kidney-Health Program

The guide recommends four practical questions:

• First, has the specific program or finished product actually been studied, or does the evidence relate only to individual ingredients or general lifestyle concepts?

• Second, are the people making medical or nutritional recommendations appropriately qualified for the advice being provided?

• Third, does the program tell consumers to continue appropriate medical monitoring and prescribed treatment rather than replace them?

• Fourth, can the claimed outcome be evaluated using established clinical measures such as eGFR, UACR, blood pressure and other relevant laboratory results rather than testimonials alone?

Frequently Asked Questions

Can The Chronic Kidney Disease Solution reverse chronic kidney disease?

This release does not make that claim. The materials reviewed do not establish through a program-specific randomized controlled clinical trial that The Chronic Kidney Disease Solution reverses CKD. CKD management should be based on appropriate medical evaluation, laboratory testing and individualized treatment. Educational lifestyle information should not be interpreted as proof of disease reversal.

Why does the guide emphasize both eGFR and UACR?

The two measurements provide different information. eGFR estimates kidney filtration, while UACR helps identify albumin leakage that can indicate kidney damage. NIDDK identifies eGFR and urine albumin as two key CKD markers. Healthcare professionals interpret these results together with medical history and other clinical information.

Is there one kidney-friendly diet that everyone with CKD should follow?

No. Nutritional needs vary according to CKD stage, laboratory results, medications and other medical conditions. Sodium, protein, potassium, phosphorus and fluid recommendations may differ between individuals. Current NIDDK and KDIGO guidance supports individualized nutrition planning, often with input from a renal dietitian or other qualified nutrition professional.

Should someone stop medication when beginning a lifestyle program?

No. The guide does not recommend stopping or changing prescribed medication because of an online program. ACE inhibitors, ARBs, SGLT2 inhibitors and other medications can have important roles in evidence-based CKD management for appropriately selected patients. Medication changes should be discussed with the prescribing healthcare professional.

About The Chronic Kidney Disease Solution

The Chronic Kidney Disease Solution is a digital educational program by Shelly Manning and published through Blue Heron Health News. The program discusses lifestyle, nutrition and general kidney-health topics in an e-book format. Current product information identifies Shelly Manning as the program’s author and describes the material as educational rather than a substitute for professional medical advice.

The program should not be interpreted as replacing CKD diagnosis, laboratory monitoring, nephrology care or prescribed treatment. Consumers with diagnosed kidney disease should discuss significant changes in diet, supplements, medication or lifestyle with an appropriate healthcare professional.

Media Contact

Shelly Manning, Media Relations.
The Chronic Kidney Disease Solution
1444 S. Entertainment Ave., Suite 410
Boise, ID 83709
Email: support@blueheronhealthnews.com
Phone: +1 (203) 872-9584

Research and Guidance Sources

Centers for Disease Control and Prevention — Chronic Kidney Disease in the United States, 2026.

National Institute of Diabetes and Digestive and Kidney Diseases — Chronic Kidney Disease Tests & Diagnosis.

National Institute of Diabetes and Digestive and Kidney Diseases — Quick Reference on UACR & GFR.

National Institute of Diabetes and Digestive and Kidney Diseases — Managing Chronic Kidney Disease.

National Institute of Diabetes and Digestive and Kidney Diseases — Healthy Eating for Adults with Chronic Kidney Disease.

Kidney Disease: Improving Global Outcomes — KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

U.S. Food and Drug Administration — Questions and Answers on Dietary Supplements.

Federal Trade Commission — Health Products Compliance Guidance.

Medical Notice: This press release discusses educational information concerning chronic kidney disease and is not medical advice. CKD diagnosis and treatment require evaluation by qualified healthcare professionals. Individuals should not change prescription medications, dialysis plans or other medical treatment on the basis of this release or any commercial health program.